Finance

Blood volume analyzer maker delays filing of second-quarter 10Q

Published in Medical Letter on the CDC and FDA, October 2nd, 2005

Daxor Corp. (DXR), a medical-instrumentation and biotechnology company, announced that on June 9, 2005, it received an informal inquiry and comments from the U.S. Securities & Exchange Commission (SEC) regarding the 2004 10K, requesting further explanation and expansion of certain information and comments that Daxor provided in various parts of the document.

As a result, Daxor has been delayed in filing the second-quarter 10Q for 2005 because of work necessitated to meet the requested changes from the SEC.

As previously announced by Daxor Corp. on August 22, 2005, Daxor filed SEC Form 12b-25 on August 12, 2005, requesting an extension of time to file...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry